share_log

InMed Pharmaceuticals | 10-K: FY2024 Annual Report

InMed Pharmaceuticals | 10-K: FY2024 Annual Report

InMed Pharmaceuticals | 10-K:2024财年年报
美股SEC公告 ·  2024/10/01 00:40

Moomoo AI 已提取核心信息

InMed Pharmaceuticals reported financial results for fiscal year 2024, with BayMedica segment revenue increasing 11% to $4.6 million and gross profit of $1.1 million. Net loss narrowed to $7.7 million from $8.0 million in FY2023. Cash position was $6.6 million as of June 30, 2024.The company made significant progress on its pharmaceutical pipeline, with INM-901 showing positive preclinical results in Alzheimer's disease treatment and INM-089 demonstrating promising effects for dry AMD. Phase 2 clinical trial results for INM-755 cream showed enhanced anti-itch activity versus control in epidermolysis bullosa patients. The company is pursuing strategic partnerships for INM-755.InMed faces near-term challenges including a Nasdaq delisting notice, with a hearing scheduled for October 31, 2024. Management expects current cash to fund operations through Q4 2024, depending on BayMedica revenue realization and operating expenses. The company continues to seek additional funding through equity financings, debt financings, or strategic transactions to extend its runway.
InMed Pharmaceuticals reported financial results for fiscal year 2024, with BayMedica segment revenue increasing 11% to $4.6 million and gross profit of $1.1 million. Net loss narrowed to $7.7 million from $8.0 million in FY2023. Cash position was $6.6 million as of June 30, 2024.The company made significant progress on its pharmaceutical pipeline, with INM-901 showing positive preclinical results in Alzheimer's disease treatment and INM-089 demonstrating promising effects for dry AMD. Phase 2 clinical trial results for INM-755 cream showed enhanced anti-itch activity versus control in epidermolysis bullosa patients. The company is pursuing strategic partnerships for INM-755.InMed faces near-term challenges including a Nasdaq delisting notice, with a hearing scheduled for October 31, 2024. Management expects current cash to fund operations through Q4 2024, depending on BayMedica revenue realization and operating expenses. The company continues to seek additional funding through equity financings, debt financings, or strategic transactions to extend its runway.
InMed Pharmaceuticals发布了2024财年的财务业绩,BayMedica部门的营业收入增长了11%,达到460万美元,毛利润为110万美元。净亏损从2023财年的800万美元减少到770万美元。截至2024年6月30日,现金状况为660万美元。该公司在其药品管道上取得了显著进展,INm-901在阿尔茨海默病治疗中的预临床结果积极,INm-089对干性年龄相关性黄斑变性表现出有希望的效果。INm-755乳膏的二期临床试验结果显示,其抗瘙痒活性优于对照组,适用于表皮松解症患者。该公司正在寻求INm-755的战略合作伙伴关系。InMed面临短期挑战,包括纳斯达克摘牌通知,听证会定于2024年10月31日举行。管理层预计目前的现金可以支持运营到2024年第四季度,具体取决于BayMedica的营业收入实现和营业费用。该公司继续寻求通过股票融资、债务融资或战略交易来获得额外资金,以延长其资金链。
InMed Pharmaceuticals发布了2024财年的财务业绩,BayMedica部门的营业收入增长了11%,达到460万美元,毛利润为110万美元。净亏损从2023财年的800万美元减少到770万美元。截至2024年6月30日,现金状况为660万美元。该公司在其药品管道上取得了显著进展,INm-901在阿尔茨海默病治疗中的预临床结果积极,INm-089对干性年龄相关性黄斑变性表现出有希望的效果。INm-755乳膏的二期临床试验结果显示,其抗瘙痒活性优于对照组,适用于表皮松解症患者。该公司正在寻求INm-755的战略合作伙伴关系。InMed面临短期挑战,包括纳斯达克摘牌通知,听证会定于2024年10月31日举行。管理层预计目前的现金可以支持运营到2024年第四季度,具体取决于BayMedica的营业收入实现和营业费用。该公司继续寻求通过股票融资、债务融资或战略交易来获得额外资金,以延长其资金链。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息